SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 70.53 |
| Enterprise Value ($M) | 70.53 |
| Book Value ($M) | 0.00 |
| Book Value / Share | 0.00 |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | 0.00 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -0.63 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ever Regal Group Ltd | -40.76 | ||
| 13G/A | Decheng Capital Management III (Cayman), LLC | 12.30 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,677 | 8,015 | 45.88 | |
| 2,089 | 3,168 | 65.94 | |
| 7,706 | 11,674 | 66.01 | |
| 1,204 | 7,294 | 16.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BOLT – Bolt Biotherapeutics, Inc. | BON – Bon Natural Life Limited |
| BTAI – BioXcel Therapeutics, Inc. | CALC – CalciMedica, Inc. |
| CAPR – Capricor Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io